News about <![CDATA[GlaxoSmithKline]]> News about en-us <![CDATA[Clinipace becomes a 'preferred provider,' starts acting like a big CRO]]> <![CDATA[Red Hatters, thank this woman for the ground you walk upon]]> <![CDATA[GSK facing new bribery allegations in Poland]]> <![CDATA[Five things you need to know today, and the shocking truth behind olestra Pringles]]> <![CDATA[Atlas Venture's newest stab at an antibiotics biotech comes out of stealth]]> <![CDATA[GlaxoSmithKline plc Cuts Jobs in China Amid Bribery Scandal (GSK)]]> <![CDATA[Market Wrap For April 2: Markets On Four-Day Winning Streak]]> U.S. stocks rose for the fourth-consecutive day as investors found plenty of positives in today's ADP National Employment Report ...

]]>
<![CDATA[Positive Changes That Can be Powered by the Private Sector]]> <![CDATA[Raleigh's BioDelivery Sciences partners with Quintiles to sell new drug]]> <![CDATA[Market Wrap For March 20: Investors Showing No Post-Fed Decision Hangover]]> U.S. stocks recovered most of Wednesday's losses after Fed Chief Janet Yellen spooked the markets a bit by hinting a rate hike ...

]]>
<![CDATA[Agenus stock falls as partner GSK misses goals in lung cancer trial]]> <![CDATA[GSK Publishes its 2013 Corporate Responsibility Report]]> <![CDATA[To the Power of 9...]]> <![CDATA[Denver GSK IMPACT Grant]]> <![CDATA[Four questions with Carl Nathan]]> <![CDATA[Market Wrap For March 10: Markets Slightly Lower On Chinese Growth Concerns]]> U.S. stocks closed the day slightly lower as investors digested news that China's exports dropped significantly.

Philadelphia Fed ...

]]>
<![CDATA[Theravance aims for Q2 split into drug development, royalty companies]]> <![CDATA[The Top Five Dow Stocks In February]]> The new year has proved to be a volatile one on the stock markets.

After seeing a sizable correction in January, the S&P 500 and Dow Jones Industrial Average (DJIA) are again hitting or near all-time highs. Here is a quick look at the five top-performing Dow stocks in the

]]>
<![CDATA[Epizyme’s loss widens on clinical trial ramp up]]> <![CDATA[Bob Ingram lays out 4 'Ds' that are bringing America down]]> <![CDATA[Geolas: RTP bridge will 'connect the whole project']]> <![CDATA[GlaxoSmithKline, Kinder Morgan And Others Insiders Have Been Buying]]> Pullbacks and sell-offs provide a perfect opportunity for investors who have faith in a company to snap up shares. Here are some stocks that have seen insider buying recently.

Aircastle

Japanese trading company Marubeni Corp. has been scooping up batches of Aircastle (NYSE: AYR) shares since last August. That included

]]>
<![CDATA[Health-care panel: Obamacare will control costs, increase accountability]]> <![CDATA[How 'personalized medicine' could make the world healthier]]> <![CDATA[Market Wrap For Febuary 20: S&P 500 Inches Closer To New Highs]]> U.S. stocks overcame mixed economic data and earning reports as the S&P 500 inches towards new all time highs and the Dow recorded an almost triple digit point gain.

Jobless claims declined less than expected while consumer prices met expectations and rose slightly. Data from the Philadelphia Fed showed manufacturing activity

]]>
<![CDATA[Agenus stock shoots up following EU biotech acquisition]]> <![CDATA[Prophylactic Hepatitis B Virus Vaccines - Global Drug Forecast and Market Analysis to 2022]]> <![CDATA[Quintiles projects increase in biopharma R&D spending]]> <![CDATA[Celgene captures cutting-edge biotechs for 'different' deals]]> <![CDATA[PYXERA Global Announces Catalyzing Growth in Emerging Markets]]> <![CDATA[InvestMaryland's chairman returns to Maryland, full-time]]> <![CDATA[Concert and Flexion on tap for biotech IPOs next week]]> <![CDATA[Biogen to take part in $230M NIH partnership on drugs for Alzheimer’s]]> <![CDATA[Triangle stocks have a bad day on Wall Street]]> <![CDATA[Market Wrap For February 3: Bears In Complete and Absolute Control]]> U.S. stocks continued its losses on an accelerated basis on Monday. Investors are in clear panic mode following a report that U.S manufacturing activity expanded at a slower pace in January.

The Dow plunged more than 300 points while the S&P 500 and Nasdaq both fell more than two percent as

]]>
<![CDATA[ZappRx adds $1M for specialty medication processing tech]]> <![CDATA[Splicing Human Genome Sciences: The post-mortem on a top Md. biotech]]> <![CDATA[Ariad up on UK article saying it might be sold]]> <![CDATA[What drug companies are the best at social media?]]> <![CDATA[Concert Pharmaceuticals files to go public in $75M offering]]> <![CDATA[Five Prime, Adimab ink deal around potential cancer treatments]]> <![CDATA[Merck plots drug R&D hub in Bay Area]]> <![CDATA[On the move: Local hires and appointments at life science companies]]> <![CDATA[Rising Short Interest In Pharmacyclics, Other Biotechs (AMGN, GILD, PCYC)]]> Among leading biotech and emerging pharmaceutical companies, the number of shares sold short in Amgen (NASDAQ: AMGN), Gilead Sciences (NASDAQ: GILD) and Pharmacyclics (NASDAQ: PCYC) grew by the largest percentages between the November 29 and December 13 settlement dates.

Medivation saw its short interest increase

]]>
<![CDATA[This week in health care: Catholic hospitals, executive pay, and Microsoft exec to rescue national exchange]]> <![CDATA[Theravance to pay GSK $60M after FDA approval, launch of COPD drug]]> <![CDATA[GlaxoSmithKline to Stop Paying Doctors to Promote Drugs]]> DailyFinance.com: Matthew Lloyd/Bloomberg via Getty Images By Ben Hirschler LONDON -- GlaxoSmithKline will stop paying doctors for promoting its drugs and scrap prescription targets for its marketing staff -- a first for an industry battling scandals over its sales ... Read more]]> <![CDATA[Agenus' stock spikes 25% on promising data from brain cancer trial]]> <![CDATA[Five things you need to know today, and the greatest resume EVER]]> <![CDATA[Fala to become Liberty Property Trust's general counsel]]>